Charles River Laboratories (CRL)
NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
$228.72-1.17%
Close 2026-07-07 · 1-day change
Reading CRL? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CRL free→NYSEHealth CareDiagnostics & ResearchSnapshot 2026-07-07
Reading CRL? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track CRL free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a mixed management execution track record. The current thesis state is intact, supported by recent strong financial performance despite being loss-making.
The market currently prices CRL at an expensive level compared to its peers, indicating high expectations. There is a low fragility tier, suggesting that the stock is not overly sensitive to negative news at this time.
Fundamentals may continue to show strength, but there is a near-term risk of missing earnings again, as the company has done in recent quarters. Management's mixed priorities, including completing divestitures and enhancing client experience, add uncertainty to future performance.
The long-term thesis hinges on the company's ability to maintain guidance and the performance of sector bellwethers like TMO, DHR, and IDXX. Positive momentum in the healthcare sector could support CRL, while any negative shifts from these peers could be detrimental.
Overall, CRL's performance will depend on management execution and sector dynamics over the next few years. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat and a focus on selective and strategic acquisitions support this improved outlook. There are no significant threats currently impacting the thesis.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Organic growth is key to recovery after recent declines. It shows demand strength.
Confirms:Q2 2026 organic revenue growth reported at least flat compared to Q1 2026.
Disproves:Q2 2026 organic revenue continues to decline year over year.
Why it matters: Earnings results will show how well the company is doing financially.
Confirms one read:Q2 2026 earnings show non-GAAP EPS above $2.06.
Confirms the other:Q2 2026 earnings report shows non-GAAP EPS below $2.06.
Why it matters: More bookings in the DSA segment would show positive demand trends. This supports revenue growth.
Confirms:DSA segment bookings increase year over year in Q2 2026.
Disproves:DSA segment bookings decline year over year in Q2 2026.
Why it matters: Stock buybacks show management's confidence. They can help keep share prices up.
Confirms:A news release about more stock buybacks beyond the $800 million left.
Disproves:No updates on stock repurchase plans or a pause in the program.
Why it matters: Changes in EPS guidance can show shifts in profit expectations. This can affect how investors feel.
Confirms one read:Non-GAAP EPS guidance raised above $11.20.
Confirms the other:Non-GAAP EPS guidance lowered below $10.70.
Why it matters: Updates on the stock buyback plan may show how much management believes in the company.
Confirms:There is an announcement of more share buybacks beyond the current $800 million plan.
Disproves:No updates or a pause in the stock repurchase program.
Why it matters: Higher margins show better efficiency and cost control.
Confirms:Non-GAAP operating margin is better than in Q1 2026.
Disproves:Non-GAAP operating margin drops more in Q2 2026.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: New acquisitions could enhance growth and align with Charles River's core strengths.
Confirms:A new acquisition that fits with main skills is announced.
Disproves:No news on acquisitions or delays in planned deals.